Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans

OBJECTIVE: Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and its relation to coronary heart disease (CHD) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: van Keulen, Danielle, Pouwer, Marianne G., Emilsson, Valur, Matic, Ljubica Perisic, Pieterman, Elsbet J., Hedin, Ulf, Gudnason, Vilmundur, Jennings, Lori L., Holmstrøm, Kim, Nielsen, Boye Schnack, Pasterkamp, Gerard, Lindeman, Jan H. N., van Gool, Alain J., Sollewijn Gelpke, Maarten D., Princen, Hans M. G., Tempel, Dennie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713386/
https://www.ncbi.nlm.nih.gov/pubmed/31461490
http://dx.doi.org/10.1371/journal.pone.0221477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713386/
https://www.ncbi.nlm.nih.gov/pubmed/31461490
http://dx.doi.org/10.1371/journal.pone.0221477

Ejemplares similares